Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 7/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL222279 | 0.89 | SIGMAR1 (0.51) | SIGMAR1TMEM97AADAT | |
| SCHEMBL15503355 | 0.77 | AADAT (0.47) | SIGMAR1TMEM97AADAT | |
| SCHEMBL15957792 | 0.74 | SIGMAR1 (0.49) | SIGMAR1TMEM97AADAT | |
| SCHEMBL24672521 | 0.73 | SIGMAR1 (0.43) | SIGMAR1TMEM97CYP2C19 | |
| SCHEMBL15514911 | 0.72 | SIGMAR1 (0.42) | SIGMAR1TMEM97AADAT | |
| SCHEMBL222561 | 0.72 | SIGMAR1 (0.42) | SIGMAR1TMEM97AADAT | |
| SCHEMBL18734805 | 0.70 | SMN1; SMN2 (0.51) | SIGMAR1CD274 | |
| SCHEMBL19880369 | 0.70 | SMN1; SMN2 (0.51) | SIGMAR1CD274 | |
| SCHEMBL19880370 | 0.70 | SMN1; SMN2 (0.51) | SIGMAR1CD274 | |
| SCHEMBL221805 | 0.68 | SIGMAR1 (0.47) | SIGMAR1TMEM97AADAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957275-B2 | Pyrazolo[1,5-A]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170362244-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362244-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | SIGMAR1 3564/4885TMEM97 3929/4885PDCD1 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.